Hypoxia News and Research

RSS

Hypoxia is a condition in which there is a decrease in the oxygen supply to a tissue. In cancer treatment, the level of hypoxia in a tumor may help predict the response of the tumor to the treatment.

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

PAH risk factors identified for systemic sclerosis patients

Researchers have identified clinical features that could help predict which patients with systemic sclerosis are likely to go on to develop pulmonary arterial hypertension (PAH) and therefore benefit most from early treatment.

13 May 2014

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the first quarter ended March 31, 2014.

12 May 2014

Promising new approach targets cancer protein to slow tumor growth

Sometimes a full-on assault isn't the best approach when dealing with a powerful enemy. A more effective approach, in the long run, may be to target the support system replenishing the supplies that keep your foe strong and ready for battle.

26 Apr 2014

John Hopkins researchers create novel optical imaging equipment for use on SARRP research platform

Researchers from John Hopkins University have created an innovative piece of optical imaging equipment for use on-board the Xstrahl Small Animal Radiation Research Platform.

From Xstrahl 17 Apr 2014

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.

16 Apr 2014

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

A $1.92 million grant from the National Institutes of Health (NIH) was awarded to a research team that focuses on new approaches for treatment of relapsed pediatric acute myelogenous leukemia (rAML), led by Yang Liu, PhD, Bothworth Chair and Director of the Center for Cancer and Immunology Research (CCIR) at Children's Research Institute of Children's National Health System, and Reuven Schore, MD, member of CCIR and attending physician in the Leukemia & Lymphoma Program of the Division of Oncology of the Center for Cancer and Blood Disorders.

9 Apr 2014

Study: Ginsenoside Rb1 attenuates neuronal damage following cerebral ischemia

Activated microglia-mediated inflammation promotes neuronal damage under cerebral hypoxic-ischemic conditions, so it is likely that inhibiting hypoxia-induced activation of microglia will alleviate neuronal damage.

7 Apr 2014

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

CardioCell LLC has just received the FDA's investigational new drug (IND) approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with chronic heart failure (CHF), which generates more than 1 million hospitalizations annually.

3 Apr 2014

Misplaced protein provides promising drug target for kidney cancer

The shortage of oxygen, or hypoxia, created when rapidly multiplying kidney cancer cells outgrow their local blood supply can accelerate tumor growth by causing a nuclear protein called SPOP-which normally suppresses tumor growth-to move out of the nucleus to the cytoplasm, where it has the opposite effect, promoting rapid proliferation.

21 Mar 2014

Proteins that regulate energy metabolism are essential for stem cell formation

Proteins that regulate energy metabolism are essential for stem cell formation, University of Washington researchers find.

21 Mar 2014

Low levels of oxygen, nitric oxide appear to have unfortunate synergy for patients with sickle cell disease

Low levels of both oxygen and the powerful blood vessel dilator nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.

21 Mar 2014

Cytoplasmic HIF-2α linked to poor prognosis in renal cell carcinoma

Cytoplasmic expression of hypoxia inducible factor-2α is associated with poor prognosis in patients with clear cell renal cell carcinoma, study findings indicate.

17 Mar 2014

Scientists uncover how inflammation and lack of oxygen cause brain damage

Scientists have uncovered how inflammation and lack of oxygen conspire to cause brain damage in conditions such as stroke and Alzheimer's disease.

14 Mar 2014

Research: Beneficial and toxic roles of brain glycogen

In 2007, in an article published in Nature Neuroscience, scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by Joan Guinovart, an authority on glycogen metabolism, reported that in Lafora Disease (LD), a rare and fatal neurodegenerative condition that affects adolescents, neurons die as a result of the accumulation of glycogen-chains of glucose.

3 Mar 2014

Research explains how cells behave when placed in low oxygen environment

Research at the University of Liverpool has explained how cells behave when placed in a low oxygen environment, a development that could have implications for cancer patients and other serious illnesses.

24 Feb 2014

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually.

20 Feb 2014

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced that it has dosed the first patient in a Phase 2 trial evaluating AKB-9778, a Tie2 activator, alone and in combination with ranibizumab (Lucentis) for the treatment of diabetic macular edema (DME). AKB-9778 is a first-in-class inhibitor of human protein tyrosine phosphatase beta (HPTPβ) that activates the Tie2 pathway to promote vascular stability, preventing abnormal blood vessel growth and vascular leak.

13 Feb 2014

Professor wins Wiley Prize for discovering how cells sense, respond to low oxygen conditions

The 13th annual Wiley Prize in Biomedical Sciences was awarded to Gregg Semenza, M.D., Ph.D., for his contribution to discovering how cells sense and respond to low oxygen conditions.

5 Feb 2014

Study shows melatonin hormone may inhibit tumor growth and cell production

An early stage study shows melatonin - a hormone that regulates the body's sleep and awake cycles - may have the potential to help slow the growth of certain breast cancer tumors, according to researchers from Henry Ford Hospital in Detroit and Foundation for Research Support of the State of S-o Paulo.

28 Jan 2014

Hypoxia News and Research

Further Reading

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

PAH risk factors identified for systemic sclerosis patients

Akebia Therapeutics reports net loss of $9.7 million for Q1 2014

Promising new approach targets cancer protein to slow tumor growth

John Hopkins researchers create novel optical imaging equipment for use on SARRP research platform

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Researchers receive NIH grant for pediatric acute myelogenous leukemia treatment

Study: Ginsenoside Rb1 attenuates neuronal damage following cerebral ischemia

CardioCell receives IND approval for Phase IIa clinical study of itMSC therapy to treat heart failure

Misplaced protein provides promising drug target for kidney cancer

Proteins that regulate energy metabolism are essential for stem cell formation

Low levels of oxygen, nitric oxide appear to have unfortunate synergy for patients with sickle cell disease

Cytoplasmic HIF-2α linked to poor prognosis in renal cell carcinoma

Scientists uncover how inflammation and lack of oxygen cause brain damage

Research: Beneficial and toxic roles of brain glycogen

Research explains how cells behave when placed in low oxygen environment

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Aerpio Therapeutics doses first patient in AKB-9778 Phase 2 trial for diabetic macular edema treatment

Professor wins Wiley Prize for discovering how cells sense, respond to low oxygen conditions

Study shows melatonin hormone may inhibit tumor growth and cell production

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News